0824 Yumanity
BioCentury & Getty Images


Reverse merger offers Yumanity faster, less risky path to NASDAQ

Aug 25, 2020 | 12:31 AM GMT

Despite continued demand for biotech IPOs, Yumanity has opted to take a less traditional route to the public markets in a move that it views as more efficient and less risky. 

On Monday, the company announced a reverse merger with Proteostasis Therapeutics

Read the full 628 word article

How to gain access

Continue reading with a
two-week free trial.